Section 6 of 6
References
177 sources
- Alshekhlee et al. (2009) (opens in a new tab)
- American Academy of Neurology myasthenic crisis quality measure (opens in a new tab)
- Antozzi et al. (2025) (opens in a new tab)
- argenx VYVGART Hytrulo wholesale acquisition cost disclosure for Colorado prescribers (2026) (opens in a new tab)
- argenx VYVGART wholesale acquisition cost disclosure for Colorado prescribers (2025) (opens in a new tab)
- Barnett-Tapia et al. (2026) (opens in a new tab)
- Benatar et al. (2022) (opens in a new tab)
- Bkemv prescribing information (2026) (opens in a new tab)
- Bradhurst et al. (2026) (opens in a new tab)
- Bril et al. (2023) (opens in a new tab)
- Bruckman et al. (2024) (opens in a new tab)
- Carr et al. (2010) (opens in a new tab)
- Cartesian Therapeutics 2026 outlook press release (2026) (opens in a new tab)
- Cartesian Therapeutics AURORA first participant press release (2025) (opens in a new tab)
- Cartesian Therapeutics corporate presentation, May 2026 (2026) (opens in a new tab)
- Cartesian Therapeutics corporate presentation, November 2026 (2026) (opens in a new tab)
- Cartesian Therapeutics Form 10-K (2026) (opens in a new tab)
- Cartesian Therapeutics Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
- Cartesian Therapeutics full year 2025 results (2026) (opens in a new tab)
- Cartesian Therapeutics K2 HealthVentures financing press release (2026) (opens in a new tab)
- Cartesian Therapeutics MG-001 clinical study protocol, version 4.2 (2024) (opens in a new tab)
- Cartesian Therapeutics MGFA 2024 presentation press release (2024) (opens in a new tab)
- Cartesian Therapeutics phase 2b 12-month results press release (2025) (opens in a new tab)
- Cartesian Therapeutics phase 2b topline results press release (2024) (opens in a new tab)
- Cartesian Therapeutics phase 2b updated results press release (2024) (opens in a new tab)
- Cartesian Therapeutics retreatment data press release (2026) (opens in a new tab)
- Cartesian Therapeutics RMAT designation press release (2024) (opens in a new tab)
- Cartesian Therapeutics second quarter 2026 results (2026) (opens in a new tab)
- Cartesian Therapeutics Special Protocol Assessment press release (2025) (opens in a new tab)
- Cartesian Therapeutics third quarter 2026 results (2026) (opens in a new tab)
- Cavalcante et al. (2024) (opens in a new tab)
- Centers for Medicare & Medicaid Services FY 2027 IPPS/LTCH PPS final rule (2026) (opens in a new tab)
- Chahin et al. (2025) (opens in a new tab)
- Choi et al. (2025) (opens in a new tab)
- Çipi et al. (2026) (opens in a new tab)
- Claytor et al. (2023) (opens in a new tab)
- ClinicalTrials.gov NCT04146051 (opens in a new tab)
- ClinicalTrials.gov NCT06193889 (opens in a new tab)
- ClinicalTrials.gov NCT06359041 (opens in a new tab)
- ClinicalTrials.gov NCT06799247 (opens in a new tab)
- ClinicalTrials.gov NCT06799247 record version 16 (opens in a new tab)
- ClinicalTrials.gov NCT07089121 (opens in a new tab)
- Dewilde et al. (2023a) (opens in a new tab)
- Dewilde et al. (2023b) (opens in a new tab)
- Dewilde et al. (2025a) (opens in a new tab)
- Dewilde et al. (2025b) (opens in a new tab)
- Di et al. (2024) (opens in a new tab)
- Dodd et al. (2025) (opens in a new tab)
- Dresser et al. (2021) (opens in a new tab)
- Engel-Nitz et al. (2018) (opens in a new tab)
- Epysqli prescribing information (2026) (opens in a new tab)
- EU Clinical Trials Information System 2024-520355-25-00 (opens in a new tab)
- FDA news release on CAR T cell REMS elimination (2025) (opens in a new tab)
- FDA Orphan Drug Designations and Approvals (2022) (opens in a new tab)
- FDA safety communication on CAR T cell REMS elimination (2025) (opens in a new tab)
- Fedak et al. (2026) (opens in a new tab)
- Furqan et al. (2024) (opens in a new tab)
- Gelinas et al. (2022) (opens in a new tab)
- Gilhus et al. (2019) (opens in a new tab)
- Gilhus et al. (2024) (opens in a new tab)
- Gilhus et al. (2026) (opens in a new tab)
- Granit et al. (2023) (opens in a new tab)
- Granit et al. supplementary appendix (2023) (opens in a new tab)
- Greco et al. (2024) (opens in a new tab)
- Greco et al. (2026) (opens in a new tab)
- Grob et al. (2008) (opens in a new tab)
- Gronseth et al. (2020) (opens in a new tab)
- Grover et al. (2026a) (opens in a new tab)
- Grover et al. (2026b) (opens in a new tab)
- Grover et al. (2026c) (opens in a new tab)
- Gusovsky Chevalier et al. (2025) (opens in a new tab)
- Gwathmey et al. (2026) (opens in a new tab)
- Habib et al. (2024) (opens in a new tab)
- Haghikia et al. (2023) (opens in a new tab)
- Harris et al. (2020) (opens in a new tab)
- Hegelmaier et al. (2026a) (opens in a new tab)
- Hegelmaier et al. (2026b) (opens in a new tab)
- Hehir and Silvestri (2018) (opens in a new tab)
- Herr et al. (2023) (opens in a new tab)
- Howard (2018) (opens in a new tab)
- Howard et al. (2017) (opens in a new tab)
- Howard et al. (2021) (opens in a new tab)
- Howard et al. (2023) (opens in a new tab)
- Howard et al. (2024) (opens in a new tab)
- Howard et al. (2026) (opens in a new tab)
- Huang et al. (2024) (opens in a new tab)
- Hughes et al. (2023) (opens in a new tab)
- ICER (2021) (opens in a new tab)
- ICER multiple myeloma final evidence report (2021) (opens in a new tab)
- Imaavy prescribing information (2026) (opens in a new tab)
- Jackson et al. (2023) (opens in a new tab)
- Jackson et al. (2025) (opens in a new tab)
- Jacob et al. (2025) (opens in a new tab)
- Jagannath et al. (2023) (opens in a new tab)
- Jiang et al. (2025) (opens in a new tab)
- Jul Jarbæk Nielsen et al. (2025) (opens in a new tab)
- Kaminski et al. (2024) (opens in a new tab)
- Katzberg et al. (2014) (opens in a new tab)
- Khateb et al. (2025) (opens in a new tab)
- Klygefa prescribing information (2026) (opens in a new tab)
- Kumar and Kim (2026a) (opens in a new tab)
- Kumar et al. (2026b) (opens in a new tab)
- Kusner et al. (2012) (opens in a new tab)
- Landfeldt et al. (2020) (opens in a new tab)
- Li et al. (2026) (opens in a new tab)
- Lien et al. (2024) (opens in a new tab)
- Lin et al. (2021) (opens in a new tab)
- Lord et al. (2026) (opens in a new tab)
- Lyman et al. (2020) (opens in a new tab)
- Managed Healthcare Executive eculizumab biosimilars article (2025) (opens in a new tab)
- Managed Healthcare Executive Uplizna IgG4-related disease approval article (2025) (opens in a new tab)
- Manolopoulos et al. (2025) (opens in a new tab)
- Massachusetts Executive Office of Health and Human Services Administrative Bulletin 24-19 (2024) (opens in a new tab)
- McLaren et al. (2026) (opens in a new tab)
- Meisel et al. (2026a) (opens in a new tab)
- Meisel et al. (2026b) (opens in a new tab)
- Mestinon prescribing information (2023) (opens in a new tab)
- Motte et al. (2024) (opens in a new tab)
- Muppidi et al. (2011) (opens in a new tab)
- Muppidi et al. (2022) (opens in a new tab)
- Myasthenia Gravis Foundation of America (opens in a new tab)
- Narayanaswami et al. (2021) (opens in a new tab)
- Narayanaswami et al. (2026a) (opens in a new tab)
- Narayanaswami et al. (2026b) (opens in a new tab)
- NCI Drug Dictionary (opens in a new tab)
- NCI Thesaurus (2026) (opens in a new tab)
- Nowak et al. (2025) (opens in a new tab)
- Parthan et al. (2024) (opens in a new tab)
- Patel et al. (2025) (opens in a new tab)
- Pesa et al. (2026a) (opens in a new tab)
- Pesa et al. (2026b) (opens in a new tab)
- Pharmaceutical Technology Descartes-08 net present value page (2024) (opens in a new tab)
- pharmaphorum Imaavy approval article (2025) (opens in a new tab)
- Phillips et al. (2022) (opens in a new tab)
- Pujades-Rodríguez et al. (2025) (opens in a new tab)
- Qi et al. (2025) (opens in a new tab)
- Reyes-Leiva et al. (2026) (opens in a new tab)
- Ribeiro et al. (2026) (opens in a new tab)
- Rodrigues et al. (2024) (opens in a new tab)
- Rousseff (2021) (opens in a new tab)
- Rystiggo prescribing information (2025) (opens in a new tab)
- Salari et al. (2021) (opens in a new tab)
- Sanders et al. (2016) (opens in a new tab)
- Sciancalepore et al. (2025) (opens in a new tab)
- Siddiqi et al. (2025) (opens in a new tab)
- Silvestri et al. (2026) (opens in a new tab)
- Smith et al. (2024) (opens in a new tab)
- Smith et al. (2026) (opens in a new tab)
- Soliris prescribing information (2026) (opens in a new tab)
- Suh et al. (2013) (opens in a new tab)
- Suzuki et al. (2026) (opens in a new tab)
- Tian et al. (2024) (opens in a new tab)
- Tice et al. (2022) (opens in a new tab)
- Ting et al. (2025) (opens in a new tab)
- Tse et al. (2025) (opens in a new tab)
- UCB RYSTIGGO pricing information (2025) (opens in a new tab)
- UCB ZILBRYSQ pricing information (2026) (opens in a new tab)
- Ultomiris prescribing information (2026) (opens in a new tab)
- Uplizna prescribing information (2025) (opens in a new tab)
- Vinciguerra et al. (2023) (opens in a new tab)
- Vissing et al. (2020) (opens in a new tab)
- Vu et al. (2022) (opens in a new tab)
- Vu et al. (2025) (opens in a new tab)
- Vu et al. (2026a) (opens in a new tab)
- Vu et al. (2026b) (opens in a new tab)
- Vyvgart Hytrulo prescribing information (2026) (opens in a new tab)
- Vyvgart prescribing information (2026) (opens in a new tab)
- Wolfe et al. (2016) (opens in a new tab)
- Wolfe et al. (2019) (opens in a new tab)
- Wong et al. (2025) (opens in a new tab)
- Wong et al. (2026) (opens in a new tab)
- Wu et al. (2024) (opens in a new tab)
- Ye et al. (2024) (opens in a new tab)
- Yoder et al. (2025) (opens in a new tab)
- Zhang et al. (2025) (opens in a new tab)
- Zhdanava et al. (2024) (opens in a new tab)
- Zilbrysq prescribing information (2026) (opens in a new tab)